Mayer Jutta S, Hees Katharina, Medda Juliane, Grimm Oliver, Asherson Philip, Bellina Mariano, Colla Michael, Ibáñez Pol, Koch Elena, Martinez-Nicolas Antonio, Muntaner-Mas Adrià, Rommel Anna, Rommelse Nanda, de Ruiter Saskia, Ebner-Priemer Ulrich W, Kieser Meinhard, Ortega Francisco B, Thome Johannes, Buitelaar Jan K, Kuntsi Jonna, Ramos-Quiroga J Antoni, Reif Andreas, Freitag Christine M
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Goethe University, Deutschordenstr. 50, 60528, Frankfurt am Main, Germany.
Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany.
Trials. 2018 Feb 26;19(1):140. doi: 10.1186/s13063-017-2426-1.
The risk for major depression and obesity is increased in adolescents and adults with attention-deficit / hyperactivity disorder (ADHD) and adolescent ADHD predicts adult depression and obesity. Non-pharmacological interventions to treat and prevent these co-morbidities are urgently needed. Bright light therapy (BLT) improves day-night rhythm and is an emerging therapy for major depression. Exercise intervention (EI) reduces obesity and improves depressive symptoms. To date, no randomized controlled trial (RCT) has been performed to establish feasibility and efficacy of these interventions targeting the prevention of co-morbid depression and obesity in ADHD. We hypothesize that the two manualized interventions in combination with mobile health-based monitoring and reinforcement will result in less depressive symptoms and obesity compared to treatment as usual in adolescents and young adults with ADHD.
This trial is a prospective, pilot phase-IIa, parallel-group RCT with three arms (two add-on treatment groups [BLT, EI] and one treatment as usual [TAU] control group). The primary outcome variable is change in the Inventory of Depressive Symptomatology total score (observer-blinded assessment) between baseline and ten weeks of intervention. This variable is analyzed with a mixed model for repeated measures approach investigating the treatment effect with respect to all three groups. A total of 330 participants with ADHD, aged 14 - < 30 years, will be screened at the four study centers. To establish effect sizes, the sample size was planned at the liberal significance level of α = 0.10 (two-sided) and the power of 1-β = 80% in order to find medium effects. Secondary outcomes measures including change in obesity, ADHD symptoms, general psychopathology, health-related quality of life, neurocognitive function, chronotype, and physical fitness are explored after the end of the intervention and at the 12-week follow-up.
This is the first pilot RCT on the use of BLT and EI in combination with mobile health-based monitoring and reinforcement targeting the prevention of co-morbid depression and obesity in adolescents and young adults with ADHD. If at least medium effects can be established with regard to the prevention of depressive symptoms and obesity, a larger scale confirmatory phase-III trial may be warranted.
German Clinical Trials Register, DRKS00011666. Registered on 9 February 2017. ClinicalTrials.gov, NCT03371810. Registered on 13 December 2017.
注意力缺陷多动障碍(ADHD)的青少年和成年人患重度抑郁症和肥胖症的风险增加,青少年ADHD可预测成人抑郁症和肥胖症。迫切需要非药物干预措施来治疗和预防这些共病。强光疗法(BLT)可改善昼夜节律,是一种新兴的重度抑郁症治疗方法。运动干预(EI)可减轻肥胖并改善抑郁症状。迄今为止,尚未进行随机对照试验(RCT)来确定这些针对预防ADHD共病抑郁症和肥胖症的干预措施的可行性和有效性。我们假设,与ADHD青少年和青年成人的常规治疗相比,这两种人工干预措施与基于移动健康的监测和强化相结合,将减少抑郁症状和肥胖。
本试验是一项前瞻性、试点IIa期平行组RCT,分为三组(两个附加治疗组[BLT,EI]和一个常规治疗[TAU]对照组)。主要结局变量是干预基线至十周期间抑郁症状量表总分的变化(观察者盲法评估)。使用重复测量混合模型分析该变量,以研究所有三组的治疗效果。将在四个研究中心筛选总共330名年龄在14 - <30岁的ADHD参与者。为了确定效应大小,样本量计划在α = 0.10(双侧)的宽松显著性水平和1-β = 80%的检验效能下,以发现中等效应。在干预结束后和12周随访时探索次要结局指标,包括肥胖、ADHD症状、一般精神病理学、健康相关生活质量、神经认知功能、昼夜节律类型和身体素质的变化。
这是第一项关于使用BLT和EI结合基于移动健康的监测和强化来预防ADHD青少年和青年成人共病抑郁症和肥胖症的试点RCT。如果在预防抑郁症状和肥胖方面至少能确定中等效应,则可能需要进行更大规模的III期验证性试验。
德国临床试验注册中心,DRKS00011666。于2017年2月9日注册。ClinicalTrials.gov,NCT03371810。于2017年12月13日注册。